Cyclerion Therapeutics Reports Zero Revenue and Increased Losses in Q2 2026

Cyclerion Therapeutics, Inc. reported a significant decline in financial performance for the second quarter of 2026, as detailed in its latest 10-Q filing. The company recorded no revenue for the three months ended June 30, 2026, compared to $93,000 for the same period in 2025. For the first half of 2026, total revenues also fell to zero from $174,000 in the prior year. The absence of revenue was attributed to the termination of an option agreement related to olinciguat, which had previously generated income.

The company's expenses reflected a mixed trend. Research and development costs plummeted to zero in the second quarter, down from $56,000 in 2025, while general and administrative expenses increased by 4% to $1.77 million. For the six months ending June 30, 2026, total expenses rose to $4.98 million, a 51% increase from $3.30 million in the same period last year. This increase was primarily driven by higher legal fees and consulting costs. Consequently, Cyclerion reported a net loss of $1.76 million for the second quarter, compared to a loss of $324,000 in the prior year, and a total net loss of $4.93 million for the first half of 2026, up from $1.75 million in 2025.

In terms of strategic developments, Cyclerion is in the process of merging with Korsana Biosciences, a transaction expected to close in the third quarter of 2026, pending shareholder approval. This merger is anticipated to shift Cyclerion's focus towards Korsana's neurodegenerative disease therapies. The company has also entered into a collaboration agreement with Medsteer SAS to develop an anesthetic delivery system, which may enhance its product offerings in the future.

Operationally, Cyclerion's cash and cash equivalents decreased to $1.39 million as of June 30, 2026, down from $3.24 million at the end of 2025. The company has one employee and relies on consultants for its operations. The filing indicates that Cyclerion's ability to continue as a going concern is in question, as it will need to secure additional funding to sustain operations beyond the anticipated merger. The company has expressed that its current cash reserves are only sufficient to fund operations until the merger closes, after which it will need to explore further financing options.

Looking ahead, Cyclerion's management has acknowledged substantial uncertainty regarding its future financial performance and operational viability. The company is actively seeking to monetize its legacy assets while focusing on the development of its treatment-resistant depression program, CYC-126. However, the success of these initiatives is contingent on the successful completion of the merger and the ability to secure necessary funding.